Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
30 hedge funds and large institutions have $19.8M invested in Cellular Biomedicine Group, Inc. in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 4 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
8% less capital invested
Capital invested by funds: $21.5M → $19.8M (-$1.67M)
9% less funds holding
Funds holding: 33 → 30 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$473K |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
+$315K |
| 3 |
State Street
Boston,
Massachusetts
|
+$266K |
| 4 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$122K |
| 5 |
Citigroup
New York
|
+$84.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$242K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$200K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$127K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$16.1K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$13.2K |
CBMG Hedge Fund Activity: Q1 2016 in Review
30 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q1 2016, worth a combined $19.8M — down 7.8% from $21.5M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CBMG and 1 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 16 added.
The largest buyer was Vanguard Group, adding an estimated $473K. The largest seller was AQR Capital Management, exiting entirely with an estimated $242K sold.
- 30 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q1 2016, down from 33 in Q4 2015.
- Funds reported $19.8M of Cellular Biomedicine Group, Inc. stock for Q1 2016, down 7.8% quarter-over-quarter.
- 1 fund opened new Cellular Biomedicine Group, Inc. positions in Q1 2016 and 4 closed out, a net change of -3 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q1 2016 was Vanguard Group, an estimated $473K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q1 2016 was AQR Capital Management, an estimated $242K sold.
Based on aggregated 13F filings for Q1 2016.